Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Operating Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Operating Margin for 16 consecutive years, with 2.11% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 441.0% to 2.11% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.8% through Dec 2025, down 554.0% year-over-year, with the annual reading at 9.8% for FY2025, 554.0% down from the prior year.
  • Operating Margin for Q4 2025 was 2.11% at Anika Therapeutics, up from 11.62% in the prior quarter.
  • The five-year high for Operating Margin was 24.07% in Q2 2021, with the low at 852.09% in Q4 2023.
  • Average Operating Margin over 5 years is 79.26%, with a median of 9.16% recorded in 2022.
  • The sharpest move saw Operating Margin tumbled -56309bps in 2022, then soared 84978bps in 2024.
  • Over 5 years, Operating Margin stood at 25.47% in 2021, then tumbled by -2211bps to 588.55% in 2022, then tumbled by -45bps to 852.09% in 2023, then surged by 100bps to 2.3% in 2024, then skyrocketed by 192bps to 2.11% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 2.11%, 11.62%, and 14.81% for Q4 2025, Q3 2025, and Q2 2025 respectively.